Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Hogl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675–84.

Article  PubMed  Google Scholar 

Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O’Keeffe S, Trenkwalder C, Hogl B, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19:1385–96.

Article  PubMed  Google Scholar 

Garcia-Borreguero D, Grunstein R, Sridhar G, Dreykluft T, Montagna P, Dom R, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med. 2007;8:742–52.

Article  PubMed  Google Scholar 

Garcia-Borreguero D, Hogl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27:277–83.

Article  CAS  PubMed  Google Scholar 

Högl B, Garcia-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12:351–60.

Article  PubMed  Google Scholar 

Benes H, Garcia-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13:589–97.

Article  PubMed  Google Scholar 

Garcia-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8:520–30.

Article  PubMed  Google Scholar 

Högl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010;257:230–7.

Article  PubMed  Google Scholar 

Garcia-Borreguero D, Allen R, Kohnen R, Benes H, Winkelman J, Hogl B, et al. Loss of response during long-term treatment of restless legs syndrome: guidelines approved by the International Restless Legs Syndrome Study Group for use in clinical trials. Sleep Med. 2010;11:956–7.

Article  CAS  PubMed  Google Scholar 

Garcia-Borreguero D, Silber MH, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.

Article  PubMed  Google Scholar 

Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13:1280–5.

Article  PubMed  Google Scholar 

Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440–4.

Article  PubMed  Google Scholar 

Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V. Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. 2019;55:74–80.

Article  PubMed  Google Scholar 

Ferre S, Garcia-Borreguero D, Allen RP, Earley CJ. New insights into the neurobiology of restless legs syndrome. Neuroscientist. 2019;25:113–25.

Article  CAS  PubMed  Google Scholar 

Garcia-Borreguero D, Garcia-Malo C, Granizo JJ, Ferre S. A randomized, placebo-controlled crossover study with dipyridamole for restless legs syndrome. Mov Disord. 2021;36:2387–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Borreguero D, Aragon AG, Moncada B, Romero S, Granizo JJ, Quintas S, et al. Treatment of sleep, motor and sensory symptoms with the orexin antagonist suvorexant in adults with idiopathic restless legs syndrome: a randomized double-blind crossover proof-of-concept study. CNS Drugs. 2024;38:45–54.

Article  CAS  PubMed  Google Scholar 

Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—History, rationale, description, and significance. Sleep Med. 2014;15:860–73.

Article  PubMed  Google Scholar 

Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121–32.

Article  PubMed  Google Scholar 

Guy W, National Institute of Mental Health (U.S.). Psychopharmacology Research Branch., Early Clinical Drug Evaluation Program. ECDEU Assessment Manual for Psychopharmacology. Rev. ed. Rockville, MD.: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.

Garcia-Borreguero D, Kohnen R, Boothby L, Tzonova D, Larrosa O, Dunkl E. Validation of the multiple suggested immobilization test: a test for the assessment of severity of restless legs syndrome (Willis-Ekbom Disease). Sleep. 2013;36:1101–9.

Article  PubMed  PubMed Central  Google Scholar 

American Academy of Sleep Medicine. AASM Manual for the Scoring of Sleep and Associated Events v2.62020.

Ondo WG, Grieger F, Moran K, Kohnen R, Roth T. Post hoc analysis of data from two clinical trials evaluating the minimal clinically important change in international restless legs syndrome sum score in patients with restless legs syndrome (Willis-Ekbom Disease). J Clin Sleep Med. 2016;12:63–70.

Article  PubMed  PubMed Central  Google Scholar 

Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67:58–63.

Article  PubMed  Google Scholar 

Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;131:902–17.

Article  PubMed  Google Scholar 

Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9–14.

Article  PubMed  Google Scholar 

Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12:431–9.

Article  PubMed  Google Scholar 

Frauscher B, Gschliesser V, Brandauer E, El-Demerdash E, Kaneider M, Rucker L, et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med. 2009;10:611–5.

Article  PubMed  Google Scholar 

Mitterling T, Heidbreder A, Stefani A, Fritz J, Ulmer H, Poewe W, et al. Natural course of restless legs syndrome/Willis-Ekbom disease: long-term observation of a large clinical cohort. Sleep Med. 2015;16:1252–8.

Article  PubMed  Google Scholar 

Ferre S, Winkelman JW, Garcia-Borreguero D, Belcher AM, Chang JH, Earley CJ. Restless legs syndrome, neuroleptic-induced akathisia, and opioid-withdrawal restlessness: shared neuronal mechanisms? Sleep. 2024. https://doi.org/10.1093/sleep/zsad273.

Article  PubMed  Google Scholar 

Ferre S. The adenosine hypothesis of restless legs syndrome. J Caffeine Adenosine Res. 2019;9:1–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yepes G, Guitart X, Rea W, Newman AH, Allen RP, Earley CJ, et al. Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol. 2017;82:951–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferre S, Kofalvi A, Ciruela F, Justinova Z, Pistis M. Targeting corticostriatal transmission for the treatment of cannabinoid use disorder. Trends Pharmacol Sci. 2023;44:495–506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferre S, Popoli P, Tinner-Staines B, Fuxe K. Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neurosci Lett. 1996;208:109–12.

Article  CAS  PubMed